These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2669801)
41. Steroid-resistant rejection in kidney-transplanted patients: is ATG treatment for three or ten days preferable? Olausson M; Mjörnstedt L; Brynger H; Blohmé I Transpl Int; 1996; 9 Suppl 1():S38-40. PubMed ID: 8959787 [TBL] [Abstract][Full Text] [Related]
42. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606 [TBL] [Abstract][Full Text] [Related]
43. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440 [TBL] [Abstract][Full Text] [Related]
44. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393 [TBL] [Abstract][Full Text] [Related]
45. Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation. Blümke M; Kirste G; Wanner U; Wilms H Transplant Proc; 1989 Feb; 21(1 Pt 2):1747. PubMed ID: 2652571 [No Abstract] [Full Text] [Related]
46. Renal transplantation at Hartford Hospital: results of combined and flexible immunosuppression. Schweizer RT; Bow L; Roper L; Hull D; Bartus SA Clin Transpl; 1988; ():147-58. PubMed ID: 3154467 [TBL] [Abstract][Full Text] [Related]
47. Adverse influence of recipient lymphoid resistance to in vitro immunosuppression on the outcome of kidney transplants. Francis DM; Dumble LJ; Bowes L; Clunie GJ; Macdonald IM Transplantation; 1988 Dec; 46(6):853-7. PubMed ID: 2974655 [TBL] [Abstract][Full Text] [Related]
48. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M; Latter DA; Loertscher R Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721 [TBL] [Abstract][Full Text] [Related]
49. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience. Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659 [TBL] [Abstract][Full Text] [Related]
51. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation. Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109 [TBL] [Abstract][Full Text] [Related]
52. Antithymocyte globulin induction and rapid steroid taper leads to excellent results in kidney transplantation with donation after cardiac death donors: importance of rejection and delayed graft function. Mai ML; Mai WK; Taner CB; Prendergast MB; Wadei HM; Gonwa TA Transplant Proc; 2013 May; 45(4):1528-30. PubMed ID: 23726612 [TBL] [Abstract][Full Text] [Related]
54. Muromonab-CD3 and antithymocyte globulin in renal transplantation. Burk ML; Matuszewski KA Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693 [TBL] [Abstract][Full Text] [Related]
55. Basiliximab: a review of its use as induction therapy in renal transplantation. Chapman TM; Keating GM Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658 [TBL] [Abstract][Full Text] [Related]
56. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients. Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313 [TBL] [Abstract][Full Text] [Related]
57. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids. Cantarovich D J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885 [TBL] [Abstract][Full Text] [Related]
58. Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients. Wechter WJ; Morrell RM; Bergan J; Rosenberg JC; Turcotte J; Schultz JR Transplantation; 1979 Nov; 28(5):365-7. PubMed ID: 392832 [TBL] [Abstract][Full Text] [Related]